Skip to main content
. 2018 Apr 20;36(19):1941–1948. doi: 10.1200/JCO.2017.76.4258

Fig 1.

Fig 1.

Predicted distant recurrence (DR) risk in years 5 to 10 since random assignment (start of adjuvant endocrine therapy) for ATAC (Arimidex, Tamoxifen, Alone or Combination) trial (A) overall population and (B) node-negative and node-positive patients. Solid vertical lines indicate cutoff points for risk groups. CTS5, Clinical Treatment Score post–5 years.